Sebelipase alfa for lysosomal acid lipase deficiency: 5‐year treatment experience from a phase 2 open‐label extension study

BACKGROUND AND AIMS: Lysosomal acid lipase deficiency is characterized by hepatomegaly and dyslipidaemia, which can lead to cirrhosis and premature atherosclerosis. Sebelipase alfa is an approved recombinant human lysosomal acid lipase. In an open‐label extension study of adults with lysosomal acid...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Liver Int
Päätekijät: Malinová, Vĕra, Balwani, Manisha, Sharma, Reena, Arnoux, Jean‐Baptiste, Kane, John, Whitley, Chester B., Marulkar, Sachin, Abel, Florian
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: John Wiley and Sons Inc. 2020
Aiheet:
Genetics and Rare Liver Diseases
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7540377/
https://ncbi.nlm.nih.gov/pubmed/32657505
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/liv.14603
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia